Core Insights - The National Healthcare Security Administration released the 2025 medical insurance negotiation results, with 7 innovative products from Innovent Biologics successfully included in the new national medical insurance drug list, enhancing patient accessibility and affordability for critical diseases like cancer and cardiovascular conditions [1][2][3] Group 1: Medical Insurance Negotiation Results - A total of 127 products participated in the negotiation, with 114 successfully included, marking an 88% success rate for innovative drugs, the highest in seven years, surpassing the 76% success rate of 2024 [2][3] - The updated national medical insurance drug list will officially take effect on January 1, 2026, increasing the total number of drugs in the list to 3,253, including 1,857 Western medicines and 1,396 traditional Chinese medicines [2][3] Group 2: Innovent Biologics' Product Inclusion - The newly included products cover significant disease areas, including lung cancer, liver cancer, gastric cancer, esophageal cancer, gynecological tumors, hematological tumors, and metabolic diseases [3][4][5][6][7] - Specific products included are: 1. **Daboshu (Sintilimab)**: New indication for advanced mismatch repair-deficient endometrial cancer [3] 2. **Xinbimin (Tislelizumab)**: Inclusion for moderate to severe thyroid eye disease, a breakthrough therapy after 70 years without effective treatment [3] 3. **Aoyixin (Leratinib)**: First-line treatment for advanced non-small cell lung cancer (NSCLC) with specific EGFR mutations [4] 4. **Dabote (Fuzuloparib)**: Targeting KRAS G12C mutation in advanced NSCLC [5] 5. **Dabole (Entrectinib)**: For ROS1-positive advanced NSCLC [6] 6. **Ruituo (Selpercatinib)**: For RET fusion-positive NSCLC and thyroid cancer [6] 7. **Jiepalai (Pirtobrutinib)**: For relapsed or refractory mantle cell lymphoma [7] Group 3: Clinical Trial Updates - At the 2025 American Society of Hematology (ASH) meeting, Innovent Biologics presented preliminary data on IBI3003, a tri-specific antibody for relapsed or refractory multiple myeloma, showing promising efficacy and manageable safety profiles [9][10] - The trial included 39 patients, with a median follow-up of 3.25 months, demonstrating an overall response rate (ORR) of 83.3% at doses ≥120 μg/kg [11][12] Group 4: Future Prospects and Collaborations - Innovent Biologics has a robust pipeline with 17 commercialized drugs and several in advanced clinical stages, indicating strong growth potential [12][13] - A strategic collaboration with Takeda aims to accelerate the global market entry of next-generation immuno-oncology and antibody-drug conjugate therapies, with a total deal value of $11.4 billion [12][13]

Core Insights - The new National Medical Insurance Directory and the first Commercial Health Insurance Innovative Drug Directory will be implemented nationwide starting January 1, 2026, showcasing the government's commitment to enhancing healthcare access [1] Group 1: National Medical Insurance Directory - Nine innovative drugs from the STAR Market have been included in the new National Medical Insurance Directory, highlighting the strength and vitality of innovative pharmaceutical companies [1] - The inclusion of products like Baiyue Shenzhou's Baihe An and Kaize Bai in the first Commercial Health Insurance Innovative Drug Directory provides broader payment pathways for cutting-edge treatments [1][4] Group 2: Innovative Drug Companies - Nearly 90% of STAR Market biopharmaceutical companies have received medical insurance support for their newly approved drugs, indicating a favorable environment for innovation [2] - Junshi Biosciences' drug, Junshida, is the only domestic PCSK9-targeted drug for statin-intolerant patients included in the new medical insurance directory [2] - Haichuang Pharmaceutical's first marketed drug, Hainan An, is set to launch in May 2025 for treating metastatic castration-resistant prostate cancer, with its inclusion in the 2025 medical insurance directory expected to enhance market promotion and patient accessibility [2] Group 3: Drug Development and Market Integration - New cancer drugs from companies like Shanghai Ailis and Yifang Biotech provide precise treatment options for major diseases, demonstrating the efficient integration of new drug reviews and medical insurance payments in China [3] - Successful renewal negotiations for innovative drugs from companies like Baiyue Shenzhou and Junshi Biosciences further expand medical insurance coverage, benefiting a wider patient population [5] Group 4: R&D Investment and Future Outlook - R&D investment among STAR Market innovative drug companies reached a new high in the first three quarters of 2025, with a year-on-year increase of over 10% and an R&D intensity of 42%, significantly surpassing the overall A-share level [6] - The continuous improvement and collaboration of support policies like medical insurance and commercial insurance are expected to foster the emergence of more world-class new drugs, contributing to the health of the Chinese population [6]

Core Insights - The National Healthcare Security Administration (NHSA) has released the 2025 National Medical Insurance Drug List, adding 114 new drugs, including 50 innovative drugs of Class A, and 19 drugs included in the first commercial insurance innovative drug list [1][4] Summary by Sections New Drug Additions - The 2025 National Medical Insurance Drug List primarily adds chemical drugs, with a rapid increase in biological products and some traditional Chinese medicine [1] - Out of the 114 new drugs, 112 were included through negotiation and bidding, while 2 were directly included from national procurement [1] - A total of 111 new drugs were approved in the last five years, with the number of Class A innovative drugs reaching a historical high of 50 [1] Financial Impact - As of October 2023, the NHSA has paid over 460 billion yuan for drugs under agreement, benefiting over 1 billion patients and driving related sales exceeding 670 billion yuan [2] - Basic medical insurance covers approximately 44% of the costs for innovative drugs, while commercial insurance covers about 7% [2] Evaluation and Selection Criteria - The selection process for new drugs has seen a low pass rate during expert reviews, with only 127 out of 311 drugs passing to the negotiation table this year [2] - Some drugs were not favored due to "involutionary innovation," where the clinical value does not significantly improve compared to existing drugs [3][4] - To be included in the list, drugs must meet at least one of three criteria: filling clinical gaps, superior efficacy, or better cost-effectiveness [4] Commercial Insurance Innovations - The newly introduced commercial health insurance innovative drug list emphasizes drug innovation and clinical value, with 19 out of 141 submitted drugs successfully negotiated for inclusion [5] - The drugs in the commercial insurance list include 9 Class A new drugs, addressing gaps in basic medical insurance coverage [5] Future Directions - The NHSA plans to continue annual adjustments to the drug list to meet evolving clinical needs and incorporate advancements in medical technology [6] - The focus will be on supporting domestic and innovative drugs, enhancing collaboration between commercial insurance and innovative pharmaceutical companies [6]

Core Viewpoint - The Hong Kong innovative drug sector continues to adjust, with the core Hong Kong Stock Connect Innovative Drug ETF (520880) experiencing fluctuations below the surface, nearing its lowest point since July. However, there is a surge in buying interest as funds have entered the market significantly in recent days, indicating active buying momentum [1][6]. Group 1: Market Performance - The Hong Kong Stock Connect Innovative Drug ETF (520880) has seen a net subscription of over 56 million yuan in the last two days, totaling over 113 million yuan [1][6]. - Leading stocks in the sector have shown a trend of more declines than gains, with companies like Kangfang Biotech and China Biopharmaceutical dropping over 2%, while CSPC Pharmaceutical rose over 2% [3][8]. Group 2: Industry Developments - Significant progress has been made in the negotiation of innovative drugs within the national medical insurance framework, with multiple products and new indications successfully included in the national medical insurance catalog. Companies like Innovent Biologics, Kangfang Biotech, and Kelun-Biotech have high negotiation success rates, which helps improve drug accessibility [3][8]. - The commercial insurance catalog is becoming an important incremental market, promoting the commercialization of innovative drugs. The overall industry is witnessing accelerated R&D, expansion of indications, and internationalization [3][8]. Group 3: Future Outlook - Innovative drugs are expected to accelerate their market penetration with the support of medical insurance, particularly in high-incidence areas with unmet clinical needs such as tumors and autoimmune diseases [3][8]. - The outbound model is continuously upgrading, enhancing the global competitiveness of Chinese innovative drug pipelines. New technologies like bispecific antibodies and targeted drugs are driving product differentiation [3][8]. - Policies continue to encourage the development of innovative drugs, providing long-term growth momentum for the industry [3][8]. Group 4: ETF Characteristics - The Hong Kong Stock Connect Innovative Drug ETF (520880) is the largest in its category, with a scale of 2.142 billion yuan and an average daily trading volume of 458 million yuan since its inception [4][12]. - The index tracked by the ETF, the Hang Seng Stock Connect Innovative Drug Select Index, has a significant concentration of leading stocks, with the top ten holdings accounting for over 72% of the index weight, indicating strong leadership in the innovative drug sector [4][11]. - The ETF is designed to be pure and comprehensive, focusing solely on innovative drug R&D companies, and it effectively controls risks associated with less liquid constituent stocks [4][10].

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical and biotechnology industry, indicating an expected return that is stronger than the market benchmark by over 5% [5]. Core Insights - The National Medical Insurance Administration is strongly encouraging the high-quality development of innovative drugs, with clear policies supporting the payment side for innovative drugs. Domestic leading innovative drug companies are entering a commercial realization phase [3][7]. - The 2025 National Medical Insurance Drug List includes 127 products, with 114 successfully added, of which 50 are innovative drugs, marking a historical high. The overall negotiation success rate reached 90%, the highest in nearly seven years [7]. - The report highlights that the domestic innovative drug market is becoming increasingly concentrated, with leading companies like Heng Rui and Xin Da Biotech significantly benefiting from the new insurance policies [7]. Summary by Sections Investment Recommendations and Targets - Recommended stocks include Heng Rui Pharmaceutical (600276, Buy), Ke Lun Pharmaceutical (002422, Buy), Xin Li Tai (002294, Hold), Ao Sai Kang (002755, Buy), Jing Xin Pharmaceutical (002020, Buy), and others [3]. Market Dynamics - The report notes that the introduction of the commercial insurance directory marks the beginning of a "new golden decade" for Chinese innovative drugs, with a focus on high clinical efficacy and value innovation [7]. - The report emphasizes that the competition in the GLP-1 market remains clear, with the entry of new drugs not significantly altering the competitive landscape for existing treatments [7].

Group 1 - The core point of the announcement is that Shanghai Pharmaceuticals Holding Co., Ltd. has successfully included its drug, Amisulpride Orally Disintegrating Tablets, in the National Medical Insurance Catalog, effective from January 1, 2026 [1][4]. - The drug is a modified formulation of Amisulpride, originally launched by Sanofi in France in 1986, and is used for the treatment of adult schizophrenia [1][4]. - The drug's registration details include a specification of 50mg and 0.2g, with approval numbers H20250041 and H20250042 [1]. Group 2 - As of the announcement date, there are no other companies in China that have listed Amisulpride Orally Disintegrating Tablets [2]. - According to the IQVIA database, the hospital procurement amount for Amisulpride oral formulations in 2024 is approximately RMB 168.41 million [3].

Core Viewpoint - Shanghai Pharmaceuticals has successfully included its amisulpride orally disintegrating tablets in the National Medical Insurance Directory, effective January 1, 2026, which is expected to enhance market share and competitiveness [1] Group 1: Company Information - Shanghai Pharmaceuticals' subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has obtained the marketing authorization for amisulpride orally disintegrating tablets [1] - The amisulpride orally disintegrating tablets are a modified formulation of amisulpride tablets originally launched by Sanofi in France in 1986, used for treating adult schizophrenia [1] - As of the announcement date, there are no other companies in China that have launched amisulpride orally disintegrating tablets [1] Group 2: Market Impact - The inclusion of amisulpride orally disintegrating tablets in the National Medical Insurance Directory is expected to expand the product's market share and improve its competitive position [1] - According to the IQVIA database, the hospital procurement amount for amisulpride oral formulations in 2024 is projected to be RMB 168.41 million [1] - The successful negotiation for inclusion in the insurance directory will provide valuable experience for the company in promoting other products [1]

Core Viewpoint - Shanghai Pharmaceuticals (601607.SH) announced that its subsidiary, Shanghai Shiyou Zhongxi Pharmaceutical Co., Ltd., has successfully negotiated to include Amisulpride orally disintegrating tablets in the National Medical Insurance Directory, effective from January 1, 2026, to December 31, 2027 [1] Group 1 - Amisulpride orally disintegrating tablets are a modified formulation of Amisulpride tablets, which were launched by Sanofi in France in 1986, and are used for the treatment of adult schizophrenia [1] - As of the date of the announcement, there are no other companies in China that have listed Amisulpride orally disintegrating tablets [1] - According to the IQVIA database, the hospital procurement amount for Amisulpride oral formulations in 2024 is projected to be 168 million yuan [1]

Core Viewpoint - The National Healthcare Security Administration (NHSA) has released the new basic medical insurance drug list for 2025, which will take effect on January 1, 2026, leading to a significant increase in the success rate of new drug negotiations, particularly for innovative drugs with high clinical value [1][2]. Group 1: New Drug Negotiation Success - The success rate for new drug negotiations in 2025 has significantly improved to 88%, up from 76% in 2024, with 114 new drugs added to the national medical insurance drug list, including 50 Class 1 innovative drugs [2][3]. - The total number of drugs in the national medical insurance drug list has increased to 3,253, enhancing coverage for critical areas such as cancer, chronic diseases, mental health, rare diseases, and pediatric medications [2]. Group 2: Unique Drug Inclusion - Among the 114 newly added drugs, 105 are unique varieties, representing 92.11% of the total, including 98 Western medicines and 7 traditional Chinese medicines [3]. - The inclusion of unique traditional Chinese medicines from companies like China Resources Sanjiu, Yiling Pharmaceutical, and others indicates a balanced representation in the new drug list [3]. Group 3: Market Potential and Growth - The inclusion of 116 drugs in the latest negotiation, particularly 11 new drugs from Heng Rui Medicine and others, is expected to lead to rapid market share growth and product volume increase due to their entry into the medical insurance directory [4][5]. - The negotiation also included new mechanism drugs, such as antibody-drug conjugates and small nucleic acid siRNA drugs, which are anticipated to drive market penetration and accessibility [5]. Group 4: Commercial Health Insurance Directory - The first commercial health insurance innovative drug directory saw intense competition, with 121 candidates but only 24 entering negotiations, resulting in 19 drugs being successfully included [6]. - The directory covers critical diseases such as Alzheimer's and multiple myeloma, with a balanced mix of imported and domestic drugs [6]. Group 5: Investment Recommendations - Companies with a significant number of innovative drugs included in the new medical insurance directory, such as Heng Rui Medicine, BeiGene, and others, are recommended for investment [9]. - Potential growth in traditional Chinese medicine products included in the new directory, such as those from China Resources Sanjiu and Yiling Pharmaceutical, is also highlighted [9].

Summary of Key Points from the Conference Call Industry Overview - The conference call focused on the pharmaceutical industry, particularly the dynamics of the healthcare insurance negotiations and the performance of innovative drugs in the market [1][2][3]. Core Insights and Arguments - **Medicare Negotiation Success Rate**: The success rate for Medicare negotiations in 2025 reached nearly 90%, indicating improved communication efficiency between the Medicare Bureau and companies. However, the elimination rate during comprehensive reviews was high, suggesting stricter audits [1][3]. - **Performance of Innovative Drugs**: The innovative drug sector has outperformed other pharmaceutical segments this year, with Hong Kong stocks showing better valuation advantages and mid-term development prospects compared to A-shares [1][5]. - **Commercial Health Insurance Directory**: The release of the commercial health insurance directory provides a benchmark for product design, despite the absence of regulatory leaders from financial oversight agencies. The Medicare Bureau's initiative to issue small cards to companies enhances their visibility [1][6][9]. - **Volume-Based Procurement Policy Changes**: The shift from comprehensive re-procurement to a pricing inquiry model allows traditional generic drug companies to secure 80% of the volume if their prices are below the benchmark, ensuring sustained performance for these companies [1][12]. - **Healthcare Fund Revenue and Expenditure**: From January to October 2025, the national healthcare fund revenue grew by 2%, while expenditures decreased by 1%. However, there is significant pressure on residents' health insurance revenue and expenditure [1][13]. Additional Important Insights - **Healthcare Visits and Trends**: In Q1 2025, the total number of visits to healthcare institutions decreased by 0.1% year-on-year, with private hospitals facing increased operational risks. Essential areas like blood and oncology are experiencing rapid growth, while ophthalmology and dentistry are growing at a slower pace [1][14]. - **Health Insurance Premiums**: Health insurance premium income remained flat at approximately 890 billion yuan, failing to meet the expected growth target of around 5% [1][15]. - **Investment Trends in the Pharmaceutical Industry**: The pharmaceutical and manufacturing sectors saw fixed asset investment growth of 11.3% from January to October 2025, indicating a marginally improving trend in the industry [1][17]. - **Flu and Medical Device Market Performance**: Despite a high flu infection rate, related companies underperformed in the secondary market. The medical device industry is experiencing slowed growth, with foreign companies facing increased competition from domestic firms [1][4][20]. Recommendations for Future Investments - **Focus on Innovative Drugs**: The investment logic for innovative drugs in 2026 will emphasize risk reduction, with a focus on clinical data, regulatory approvals, and financial partnerships. The expected return rate for recommended innovative and performance-driven stocks is projected to be between 20% and 30% [1][7][24]. - **Key Stock Picks**: Companies such as Ruimaite, Fenghuang Hanlin, and Hualing Pharmaceutical are highlighted for their growth potential and market capabilities. The focus will also be on companies with strong clinical trial data and innovative product pipelines [1][25][28]. Conclusion - The pharmaceutical industry is navigating a complex landscape with evolving Medicare policies, competitive pressures, and investment opportunities in innovative drugs. The insights from the conference call provide a comprehensive overview of the current state and future outlook of the industry, emphasizing the importance of strategic investment choices in a challenging environment [1][30].